A recent study found that LAD1 is associated with malignant and aggressive human breast tumors, and the authors have proved through in vitro studies, animal models, and clinical data that the widespread expression of LAD1 acts as a substrate for the downstream phosphorylation of the EGF pathway [17,27]. This evidence concerns the gene EGF and breast neoplasm.